Priced for one buyer, wanted by many: management describes new sources of demand converging on the same thing it already
The model's full reasoning — Q3 2018 call → NOWe need answer YES/NO based on transcript. Need identify phenomenon: existing output demanded by multiple sources, widening demand base, management responding, numbers lag. Transcript: Agios Pharmaceuticals. Products: TIBSOVO (ivosidenib) for IDH1 mutant relapsed/refractory AML, IDHIFA (enasidenib) for IDH2. They are launching TIBSOVO. Demand for existing product? They discuss expanding indications: TIBSOVO in newly diagnosed AML not eligible for standard therapies, sNDA planned. Also frontline AML combinations, solid tumors (cholangiocarcinoma, glioma), MDS. But are these new sources of demand already transacting? No, mostly clinical development, not approved for those uses. The question asks "demand for same thing company already makes" - existing product TIBSOVO approved for relapsed/refractory AML. Are there multiple sources of demand for that existing approved indication? They mention testing rates, prescribers, payer mix. But demand base widening? They have launch in U.S. only. No new geographies/channels. They mention "approximately 25% to 30% of newly diagnosed patients may not receive any standard therapies" and sNDA for newly diagnosed AML. But that's not yet approved; demand for new use not yet available. So no. Need answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
LINC · Q1 2024 → YESThe question is about whether management describes demand for the same thing the company already makes coming from more than one direction at once, with specific criteria. YES Management describes the core offering—curriculum and training capabilities already in place—as now being applied in a new direction: B2B corporate upskilling contracts (e.g., the CMC agreement) alongside campus-based student programs. They explicitly state they are pursuing additional employer contracts and expanding corporate partnerships, with the new 5-year, $6 million CMC deal representing real, recent revenue that contributed nothing to the reported quarter and is still ramping up through site setup and staffing. This meets all three criteria as a single coherent development.
OPAD · Q3 2023 → YESThe question is about whether management describes demand for the same thing the company already makes coming from more than one direction at once, with specific criteria. YES The transcript shows management describing demand for renovations (already part of their core iBuyer operations) now coming from multiple directions: their own inventory, third-party B2B clients (nearly 50 clients, 127% increase in closed projects), and soon homeowners via Rental Captain.
PFIE · Q1 2023 → YESThe question is about whether management describes demand for the same thing the company already makes coming from more than one direction at once, with the demand base widening recently, and manageme...